Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

Original reporting
Published Nov 5, 2026, 7:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 7:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable — source image
Decision brief

The 30-second read

$ADPTBullishHigh
01

Why it matters

Guidance raise and positive EBITDA signal operational momentum, but Medicare payment structure remains a risk.

02

Market read

Earnings call provides fresh guidance that could move ADPT and influence the broader precision‑medicine sector.

03

What to watch

Potential headwinds from CMS draft rate errors and limited Medicare bundled payments could curb profitability.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Adaptive Biotechnologies discussed Q3 performance and future growth levers for its ClonoSeq platform.

Company-level read

Ticker impact

$ADPTBullishHigh confidence
Context

Q3 results reported $83.9M revenue and raised full-year MRD revenue guidance to $276M-$286M.

Expected impact

potential upside as investors price in higher MRD revenue outlook

Evidence & confidence

The raised guidance exceeds prior expectations and reflects double‑digit growth, likely supporting a price rally.

Market effects

Higher MRD revenue guidance may boost sentiment in the immunosequencing and precision oncology sector.

Positive impact on US biotech equities, especially small‑cap innovators.

Limited to niche biotech space; no broad market effect.

Counterpoint

Guidance may be overly optimistic given Medicare ASP pressure and uncertain CMS rate finalization.

Key entities

  • Adaptive Biotechnologies

    US‑listed biotech firm (ticker ADPT) focusing on immunosequencing.

  • Chad Robins

    CEO of Adaptive Biotechnologies.

  • Kyle Piskel

    CFO of Adaptive Biotechnologies.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.

$ADPTHighAI 8/10

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genet